SynthesisEuropean thyroid journal2026
Recurrence risk of differentiated thyroid cancer treated with total or hemithyroidectomy: systematic review and meta-analysis.
Synthesis in European thyroid journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Differentiated thyroid carcinoma (DTC) is traditionally treated with total thyroidectomy (TT); however, hemithyroidectomy (HT) has been increasingly used. Previous analyses on DTC recurrence rate with HT and TT have yielded inconsistent results; this study aimed to bridge this gap. Methods: Searches were conducted in PubMed/MEDLINE and Embase. Furthermore, references of previous systematic reviews were screened to extend the search until May 2025. Specific data on recurrence rate were independently extracted from the included studies by two observers and then pooled using a random-effect model. The primary endpoint was the risk difference (RD) in cancer recurrence rate between HT and TT. The secondary endpoints included recurrence prevalence (RP) for TT and HT and odds ratio (OR) comparing HT with TT. Results: A total of 2,556 papers were initially identified, and 46 retrospective studies were included. The overall quality of the studies was satisfactory. In total, 98,604 patients were treated with TT (n = 75,531) or HT (n = 23,073). The proportion meta-analyses revealed a pooled RP of 5.8% in TT and 8.1% in HT. The HT group had a significantly higher probability of DTC recurrence than the TT group (OR = 1.56, 95% CI = 1.47-1.66, I 2 = 85%). The RD meta-analysis revealed that the recurrence rate was significantly higher in the HT group than in the TT group, by 3% (95% CI = 3-4, I 2 = 87%). Conclusion and relevance: The DTC recurrence rate following HT is significantly higher than that observed following TT. Thyroid specialists should consider this finding when tailoring initial treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.